Niagen Bioscience Reports 38% Revenue Growth to $30.5 Million in Latest Quarter

Niagen Bioscience, Inc. reported significant financial improvements in its latest quarterly results, with net sales reaching $30.5 million for the three months ended March 31, 2025, a 38% increase from $22.2 million in the same period last year. The company achieved a net income of $5.1 million, compared to a net loss of $492,000 in the first quarter of 2024. This turnaround reflects a successful strategy in expanding its product offerings and enhancing operational efficiencies, as evidenced by a gross profit of $19.3 million, up 44% from $13.5 million year-over-year.

The company's revenue growth was driven primarily by its Consumer Products segment, which saw sales increase by 24% to $21.5 million, largely due to a $4 million rise in e-commerce sales. The Ingredients segment experienced a remarkable 100% increase in sales, totaling $8.2 million, attributed to higher demand for food-grade Niagen® and the introduction of pharmaceutical-grade Niagen® in late 2024. The Analytical Reference Standards and Services segment also contributed to the overall growth, albeit at a smaller scale, with sales rising to $811,000.

Operationally, Niagen Bioscience has made strategic adjustments, including an amendment to its lease in Longmont, Colorado, which extends through October 2030 and involves a remeasurement of lease liabilities and right-of-use assets. The company also reported a significant recovery of credit losses, which positively impacted its general and administrative expenses. As of March 31, 2025, the company had cash and cash equivalents of $55.6 million, providing a solid liquidity position to support ongoing operations and potential growth initiatives.

Looking ahead, Niagen Bioscience anticipates that its current cash reserves and projected sales will be sufficient to meet its financial obligations over the next twelve months. However, the company may seek additional capital to fund long-term strategic objectives. The management remains optimistic about the future, citing ongoing demand for its products and the potential for further market expansion, particularly in the pharmaceutical-grade segment. The company continues to focus on enhancing its research and development efforts to solidify its position in the growing NAD+ market.